Calithera Biosciences Inc represents a commitment to developing cutting-edge therapies in oncology and immuno-oncology. The company focuses on discovering and commercializing novel, small-molecule drugs that target tumor metabolism and the tumor microenvironment. By leveraging their scientific expertise, Calithera Biosciences aims to create innovative treatment options for cancer patients. With a dedication to scientific rigor and collaboration, they strive to improve patient outcomes and provide hope for those affected by cancer. Calithera Biosciences Inc believes in the power of science and innovation to make a meaningful impact in the fight against cancer.

Calithera Biosciences Inc primarily operates in the United States.

Calithera Biosciences Inc has achieved several significant milestones. The company has successfully developed a pipeline of novel cancer therapies and conducted clinical trials for various indications. It has obtained positive results in Phase I/II studies, showcasing the effectiveness and safety of its therapies. Calithera Biosciences has also secured strategic collaborations with renowned pharmaceutical companies, enabling further development and commercialization opportunities. The company's achievements demonstrate its commitment to advancing innovative treatments and addressing unmet medical needs in the field of oncology.

Calithera Biosciences Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs targeting tumor metabolism and tumor immunology. Founded in 2010, Calithera has successfully emerged as a leader in the field of cancer research. The company's extensive expertise and cutting-edge research have led to the development of innovative therapies that aim to improve the lives of patients with various types of cancer. Calithera Biosciences Inc has established collaborations with renowned academic institutions and industry partners to advance their pipeline of potential breakthrough treatments. With a strong commitment to scientific excellence, Calithera Biosciences Inc continues to strive towards transforming the landscape of cancer treatment.

The main competitors of Calithera Biosciences Inc in the market include companies such as Incyte Corporation, Exelixis Inc, and Blueprint Medicines Corporation. These companies also operate in the biopharmaceutical sector and focus on developing innovative therapies for the treatment of various diseases. However, Calithera Biosciences Inc sets itself apart through its unique therapeutic approaches, cutting-edge research, and strategic partnerships. By continuously advancing its pipeline and addressing unmet medical needs, Calithera Biosciences Inc aims to remain a competitive player in the biotech industry.

Calithera Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

Calithera Biosciences Inc operates as a clinical-stage biopharmaceutical company. The company focuses on discovering and developing small molecule drugs targeting tumor and immune cell metabolism. It aims to develop therapies to treat patients with cancer by targeting the metabolic requirements of specific tumor and immune cell subsets. Calithera Biosciences Inc is committed to advancing its programs and exploring new therapeutic areas that have the potential to improve outcomes for patients.

KGV-d ei saa praegu Calithera Biosciences jaoks arvutada.

KUV-d ei ole võimalik hetkel Calithera Biosciences jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Calithera Biosciences on 3/10.

Praegu ei saa Calithera Biosciences käivet arvutada.

Praegu ei ole võimalik kasumit Calithera Biosciences jaoks arvutada.

Calithera Biosciences Inc is an emerging biopharmaceutical company specializing in the development of novel cancer therapies. The company's business model consists of three core areas: research and development, clinical trials, and marketing. In research and development, Calithera Biosciences focuses on identifying and developing therapies based on enzymes and metabolic processes. These approaches aim to disrupt cancer metabolism and thereby hinder or stop tumor growth. The company has several innovative products in the pipeline developed in this way. In the field of clinical trials, Calithera Biosciences collaborates closely with doctors and researchers at universities and hospitals. The company conducts clinical trials to demonstrate the effectiveness and safety of its therapies and to obtain the necessary regulatory approvals. This phase evaluates the potential of the products and, if necessary, improves them before they are later released for marketing. The marketing and sales of Calithera Biosciences' products are carried out through its sales and marketing division. The company has previously formed partnerships with major pharmaceutical and biotech companies to distribute and market its products. However, Calithera Biosciences also retains the possibility of successfully establishing its products in the market itself. One of the company's main products is CB-839, a selective inhibitor of glutamine metabolism used in cancer treatment. This product is currently in various stages of development and is being tested in clinical trials. It is characterized by high effectiveness and tolerability. Calithera Biosciences also plays an important role in preclinical research. The company continuously investigates new therapeutic approaches and identifies promising drug candidates that can be utilized by other individuals and companies through licensing agreements. In the past, the company has licensed its technology to other companies to increase its income. The company is also financially well-positioned and has sufficient resources to further develop its pipeline - the collection of drugs under development. It has successfully raised investments from venture capital investors as well as private and institutional investors in the past. Overall, Calithera Biosciences Inc has a promising business model focused on the development of novel cancer therapies. Its innovative research, close collaboration with other institutions, and excellent financing make the company an important player in the biopharmaceutical industry.

Calithera Biosciences maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Calithera Biosciences jaoks arvutada või ettevõte ei maksa dividende välja.

Calithera Biosciences ISIN on US13089P1012.

Calithera Biosciences WKN on A12AQH.

Calithera Biosciences tähis on CALA.

Viimase 12 kuu jooksul maksis Calithera Biosciences dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Calithera Biosciences tõenäoliselt dividendi summas 0 USD.

Calithera Biosciences praegune dividenditootlus on .

Calithera Biosciences maksab kvartaalset dividendi. See makstakse välja kuudel .

Calithera Biosciences maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Calithera Biosciences on liigitatud sektorisse 'Tervis'.

Viimase Calithera Biosciences dividendide saamiseks 4.8.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 4.8.2024.

Viimane dividendimakse toimus 4.8.2024.

Aastal 2023 maksis Calithera Biosciences 0 USD dividende.

Calithera Biosciences dividendid makstakse välja USD.